Arcus Biosciences Inc (RCUS)

Currency in USD
10.38
+0.23(+2.27%)
Closed·
10.58+0.20(+1.93%)
·
RCUS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
RCUS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.0710.40
52 wk Range
6.5018.98
Key Statistics
Prev. Close
10.15
Open
10.12
Day's Range
10.07-10.4
52 wk Range
6.5-18.98
Volume
548.44K
Average Volume (3m)
934.05K
1-Year Change
-42.11%
Book Value / Share
5.18
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RCUS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
28.36
Upside
+173.25%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Arcus Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy

Arcus Biosciences Inc Company Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Arcus Biosciences Inc SWOT Analysis


HIF-2alpha Promise
Arcus Biosciences' HIF-2alpha inhibitor program, led by casdatifan, shows potential in renal cell carcinoma treatment, driving investor interest and analyst optimism
Financial Challenges
Despite promising pipeline, Arcus operates at a loss with negative EPS projections, reflecting typical biotech sector challenges and need for careful financial management
Competitive Edge
Explore how Arcus positions itself in the oncology space, leveraging combination therapies and benefiting from setbacks in competing anti-TIGIT programs
Future Catalysts
Analyst price targets range from $14 to $29, with upcoming clinical data readouts and trial results potentially driving significant stock performance in 2025-2026
Read full SWOT analysis

Arcus Biosciences Inc Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of -1.14 missed forecast of -1.02; revenue of $28M fell short of $38.61M projection
  • Strong cash position of $1B maintained; 2025 expected to be peak year for R&D expenses
  • Full-year 2025 revenue guidance of $75-90M reaffirmed despite Q1 miss
  • Strategic focus on castadefan development and AstraZeneca collaboration for RCC market
  • Stock recovered 1.85% in aftermarket trading following 9.17% drop during regular hours
Last Updated: 06/05/2025, 22:38
Read Full Transcript

Compare RCUS to Peers and Sector

Metrics to compare
RCUS
Peers
Sector
Relationship
P/E Ratio
−3.7x−1.2x−0.5x
PEG Ratio
4.05−0.050.00
Price/Book
2.0x1.7x2.6x
Price / LTM Sales
4.2x8.3x3.3x
Upside (Analyst Target)
140.8%279.7%38.7%
Fair Value Upside
Unlock27.7%5.0%Unlock

Analyst Ratings

11 Buy
2 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 28.36
(+173.25% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-- / -1.12
Revenue / Forecast
160.00M / 32.86M
EPS Revisions
Last 90 days

RCUS Income Statement

People Also Watch

18.26
SRPT
+1.11%
2.980
NUVB
+3.47%
21.18
ARWR
+2.27%
13.38
DYN
+2.92%

FAQ

What Stock Exchange Does Arcus Biosciences Trade On?

Arcus Biosciences is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Arcus Biosciences?

The stock symbol for Arcus Biosciences is "RCUS."

What Is the Arcus Biosciences Market Cap?

As of today, Arcus Biosciences market cap is 1.11B.

What Is Arcus Biosciences's Earnings Per Share (TTM)?

The Arcus Biosciences EPS (TTM) is -3.07.

When Is the Next Arcus Biosciences Earnings Date?

Arcus Biosciences will release its next earnings report on 10 Nov 2025.

From a Technical Analysis Perspective, Is RCUS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Arcus Biosciences Stock Split?

Arcus Biosciences has split 0 times.

How Many Employees Does Arcus Biosciences Have?

Arcus Biosciences has 627 employees.

What is the current trading status of Arcus Biosciences (RCUS)?

As of 27 Aug 2025, Arcus Biosciences (RCUS) is trading at a price of 10.38, with a previous close of 10.15. The stock has fluctuated within a day range of 10.07 to 10.40, while its 52-week range spans from 6.50 to 18.98.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.